导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 24.15% | 254/4773 |
| 近一周 | -5.06% | 5332/5467 |
| 近一月 | 2.95% | 101/5421 |
| 近一季 | 5.91% | 352/5238 |
| 近半年 | 3.15% | 1094/4931 |
| 近一年 | 21.87% | 370/4400 |
| 近两年 | 54.07% | 1380/2954 |
| 近三年 | 31.40% | 1019/2253 |
| 成立以来 | 84.25% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
18.69% 20/4961 |
-11.43% 4288/5312 |
- - |
- - |
| 2025 | 1.66% 3221/4813 |
-4.28% 3153/3635 |
-1.43% 3161/4076 |
6.88% 3494/4524 |
0.81% 1754/4813 |
| 2024 | 2.42% 1974/3463 |
1.62% 868/2808 |
-3.07% 1296/3014 |
7.58% 2808/3129 |
-3.34% 2330/3463 |
| 2023 | 11.15% 76/2656 |
3.19% 1243/2280 |
-4.37% 1154/2385 |
8.89% 11/2515 |
3.44% 57/2655 |
| 2022 | 13.00% 8/2207 |
20.02% 7/1919 |
9.51% 281/2016 |
-0.14% 10/2113 |
-13.91% 2073/2208 |
| 2021 | 36.56% 46/1822 |
-1.79% 542/1255 |
20.10% 153/1330 |
39.36% 3/1466 |
-16.92% 1638/1822 |
| 2020 | 29.62% 533/1250 |
-14.49% 961/1022 |
3.32% 940/1060 |
14.67% 262/1152 |
- - |
| 2019 | 15.53% 691/1092 |
24.29% 514/748 |
-4.37% 422/797 |
-5.95% 798/844 |
3.36% 837/912 |
| 2018 | -32.00% 513/834 |
- - |
- - |
- - |
-12.71% 476/691 |
| 2017 | 7.26% 320/714 |
- - |
- - |
- - |
- - |
| 2016 | 4.67% 61/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 招商中证煤炭等权指数(LOF)A VS. 长安沪深300非周期A(740101) |